What have we learned from the IL28 receptor knockout mouse?

J Interferon Cytokine Res. 2010 Aug;30(8):579-84. doi: 10.1089/jir.2010.0061.

Abstract

The recently discovered type III interferons (IFNs), also known as IFN-lambda, are part of the early innate immune response against viral infections. The IFN-lambda system closely resembles the type I IFN (IFN-alpha/beta) system in terms of expression after virus infection as well as intracellular signaling and activation of antiviral host factors in susceptible cells. However, in contrast to type I IFN, which signals through a universally expressed cell surface receptor, IFN-lambda uses a distinct receptor complex (IL28R) for signaling, which is expressed on a limited range of cell types. Until recently both the contribution of type III IFN to antiviral resistance as well as the exact nature of IL28R-expressing cells in vivo remained elusive. In this review we discuss data obtained from the experiments with IL28Ralpha(0/0) mice that demonstrated the role of IFN-lambda in viral defense in vivo. We further discuss the experiments that identified the cell types in various organs that express functional IFN-lambda receptors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / immunology*
  • Antiviral Agents / therapeutic use
  • Cytokines / immunology*
  • Cytokines / therapeutic use
  • Gene Expression Regulation
  • Humans
  • Immunity, Innate
  • Interferon Type I / immunology*
  • Interferon Type I / therapeutic use
  • Mice
  • Mice, Knockout
  • Receptors, Cytokine / genetics
  • Receptors, Cytokine / immunology
  • Receptors, Cytokine / metabolism*
  • Signal Transduction
  • Virus Diseases / drug therapy
  • Virus Diseases / immunology*

Substances

  • Antiviral Agents
  • Cytokines
  • Interferon Type I
  • Receptors, Cytokine
  • interferon-lambda protein, mouse
  • interleukin 28alpha receptor